Peter Bloch, CPA, CAChief Executive Officer and Chairman of the Board
Mr. Bloch has served as the Company’s Chief Executive Officer since March 2013, and was previously the company’s Chief Financial Officer. Mr. Bloch is a Chartered Accountant with a track record of building both public and private technology companies, mainly in the Life Sciences industry. His past 25 years of executive management experience includes CFO and Joint Interim CEO of Sanofi Canada Inc., CFO of Intellivax and Founder of Tribute Pharmaceuticals. Mr. Bloch also served as CFO of Gennum and Just Energy, both TSX listed Companies. These companies have ranged in size from start-ups to revenues of over $2 billion. In these roles Mr. Bloch has secured significant funding for both private and public companies, including experience with Initial Public Offerings. Mr. Bloch has been on a number of both public and private company’s board of directors.
Michal PrywataCo-Founder and Chief Operating Officer
Mr. Prywata is the co-founder of Bionik Laboratories and has served as the company’s Chief Operating Officer since March 2013, and was previously the company’s Chief Executive Officer. He studied biomedical engineering at Ryerson University and has a proven track record of inventing and winning technology showcases. While attending Ryerson, Mr. Prywata co-invented the world’s first robotic, prosthetic arm that is controlled by brain signals. Equally impressive is his strong understanding of developing technologies that address significant and untapped markets. He is responsible for raising the initial capital to found Bionik and turn numerous concepts into products.
Hermano Krebs, Ph.D., M.S.Chief Science Officer and Director
Dr. Krebs joined Bionik during the acquisition of Interactive Motion Technologies and has served as the Company's Chief Science Officer since April 2016. Prior to joining Bionik, Dr. Krebs was the Co-Founder and Chairman of the Board of Directors of Interactive Motion Technologies. Dr. Krebs is a Principal Research Scientist and Lecturer at the Massachusetts Institute of Technology, Newman Laboratory for Biomechanics and Human Rehabilitation. He also holds affiliate positions as an Adjunct Professor at University of Maryland School of Medicine, Department of Neurology and in the Division of Rehabilitative Medicine, as a Visiting Professor at Fujita Health University, Department of Physical Medicine and Rehabilitation, Japan, as a Visiting Professor at Newcastle University, Institute of Neuroscience, UK, and as a Visiting Professor at Osaka University, Department of Mechanical Engineering, Japan.
Dr. Krebs is a pioneer in the design, development, clinical use, and research of robots used to administer rehabilitation therapy to patients with neurological injury, and was recognized as such with the prestigious Institute of Electrical and Electronics Engineers (IEEE) INABA Technical Award for Innovation leading to Production in 2015. This award recognizes original innovative research and concepts that have evolved into commercialized products. In 2014, Dr. Krebs was nominated as Fellow of the IEEE for his contributions to rehabilitation robotics and the understanding of neuro-rehabilitation.
Dr. Krebs holds numerous foundational patents for the use of robotic technology in rehabilitation and has been published in more than 200 peer-reviewed scientific and clinical publications.
Jules Fried, J.D.Vice President, U.S. Operations
Mr. Fried joined Bionik during the acquisition of Interactive Motion Technologies and has served as the Company’s Vice President, U.S. Operations since April 2016. Prior to joining Bionik, Mr. Fried was Chief Executive Officer of Interactive Motion Technologies. Mr. Fried is a serial entrepreneur and experienced early stage executive, having built and led a two-time Inc. 500 capital equipment manufacturer as a founding management team member. He is also a founder and member of the Board of Directors of First Commons Bank, one of the fastest growing banks in the nation and was a principal in Atlantic VIC, a technology venture development firm. Earlier in his career, Mr. Fried was a partner in the law firm of McDermott, Will & Emery, having co-founded a boutique health care law firm which became their Boston office. Mr. Fried holds a J.D. degree, cum laude, from the University of Michigan Law School and is a graduate of Princeton University.
Leslie N. Markow, CPA, CA, CPA (Illinois), C.Dir.Chief Financial Officer
Ms. Markow has served as the Company’s Chief Financial Officer since September 2014. She has over 25 years of finance and accounting leadership experience and holds a CPA and CA in Canada, US CPA (Illinois) and Chartered Director designations. Ms. Markow is the former Chief Financial Officer of Stewardship Ontario and Blue Ocean NutraSciences Inc., and Director of Client Service for Resources Global Professionals, a Nasdaq-listed global consulting firm. For 11 years she held various positions, including Chief Administrative Officer at SunOpta Inc. a Nasdaq/TSX listed public company. Ms. Markow started her career in 1983 with PricewaterhouseCoopers, ultimately holding a position as Senior Audit Manager. She is a member of the Board of Directors and Chairperson of the Audit Committee of Jemtec Inc. Ms. Markow also is a member of Financial Executives Canada, where she is a past National Board Director, Toronto Board Director, Toronto Chapter President and the winner of the Toronto Leadership Award. She is a faculty member of The Directors College, which is a joint venture of McMaster University and The Conference Board of Canada.
Timothy A. McCarthy, MBAChief Commercialization Officer
Timothy A. McCarthy joins the Bionik team having recently served as the Chief Executive Officer of Medical Compression Systems, Inc., a medical device company specializing in compression therapy to prevent DVT and improve wound healing for joint replacement patients. He was recruited as the top executive at MCS to lead a commercial stabilization and turnaround effort in order to prepare the company for an M&A process seeking a strategic partner. Prior to that, Mr. McCarthy served as the President and CEO of iWALK, Inc. (now known as BionX Medical Technologies), a venture backed medical robotics company commercializing the Massachusetts Institute of Technology ("MIT") invented BiOM System, the world's first and only actively powered lower limb bionic prosthesis to normalize gait. While at iWALK, Inc. Mr. McCarthy was responsible for leading the final product development and commercial sales strategy that led to the successful establishment of a long-term market foothold for this new category of healthcare technology products. In addition, Mr. McCarthy served at Össur Americas as Vice President of Sales and Marketing, where he was promoted to the top commercial executive and leader of a sales and marketing restructuring and growth effort, resulting in above budget attainment each year and 4.5x revenue growth during his nine year tenure. Mr. McCarthy also held sales leadership roles at the Chattanooga Group, Inc. (now known as DJO Global). Over the course of his career Mr. McCarthy has proven to be instrumental in the expansion of public, private and startup healthcare technology and medical device companies.
Mr. McCarthy graduated cum laude from Northeastern University with a Bachelor of Science in Business Administration and received his Master of Business Administration from the University of California in Los Angeles.
Malcolm G. BockVice President of Engineering
Mr. Bock previously served as the Vice President of Engineering at Respiratory Motion, where he was responsible for creating a product pipeline and technology roadmap, and bringing the company's first product from concept to launch in 10-months' time. Prior to that, Mr. Bock served as the Senior Director of Global R&D for Covidien Ltd., a spin-off of Tyco International, where he was responsible for R&D and launching 15 new products, including both durable electro-mechanical systems and single-use devices, over a 10-year period. In 2011, he was awarded Covidien Inventor of the Year. Over the course of his career, Mr. Bock has launched over 38 new products and was awarded Best Divisional Vitality Index, and Best New Product for his work at Covidien. He has also been awarded 30 patents, with an additional 28 patents pending.